An expanded access record providing copper histidinate in Menkes Disease, sponsored by Sentynl Therapeutics, Inc.. Approved for marketing at 20 sites in United States. Open to participants aged 0 Years to 6 Years. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Sentynl Therapeutics, Inc. (part of Zydus Lifesciences Limited) · Expanded access
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This expanded access protocol provides subcutaneous copper histidinate for Menkes disease patients under 6 years of age.
Sentynl Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
First submitted after Sentynl Therapeutics, Inc. became part of Zydus Lifesciences Limited.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
copper histidinate for subcutaneous injection
Also known as: CUTX-101
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Menkes Kinky Hair Syndrome